-
1
-
-
0022966964
-
Follicular lymphoma:prognostic factors for response and survival
-
Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma:prognostic factors for response and survival. J Clin Oncol 1986;4:1470-1480.
-
(1986)
J Clin Oncol
, vol.4
, pp. 1470-1480
-
-
Gallagher, C.J.1
Gregory, W.M.2
Jones, A.E.3
-
2
-
-
0037395994
-
Overview of non-Hodgkin's lymphoma. Biology, staging and treatment
-
Fisher RI. Overview of non-Hodgkin's lymphoma. Biology, staging and treatment. Semin Oncol 2003;30:3-9.
-
(2003)
Semin Oncol
, vol.30
, pp. 3-9
-
-
Fisher, R.I.1
-
3
-
-
14144249536
-
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab
-
Horning SJ, Younes A, Jain V, et al. efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-719.
-
(2005)
J Clin Oncol
, vol.23
, pp. 712-719
-
-
Horning, S.J.1
Younes, A.2
Jain, V.3
-
4
-
-
12944275472
-
131I-tositumomab therapy as initial treatment for follicular lymphoma
-
Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
-
(2005)
N Engl J Med
, vol.352
, pp. 441-449
-
-
Kaminski, M.S.1
Tuck, M.2
Estes, J.3
-
5
-
-
0035478728
-
Pivotal study of iodine i 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
-
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3918-3928
-
-
Kaminski, M.S.1
Zelenetz, A.D.2
Press, O.W.3
-
6
-
-
0034017954
-
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
-
Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-1323.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1316-1323
-
-
Vose, J.M.1
Wahl, R.L.2
Saleh, M.3
-
7
-
-
2342622100
-
Tositumomab and iodine i 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
-
Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1469-1479.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1469-1479
-
-
Davies, A.J.1
Rohatiner, A.Z.2
Howell, S.3
-
8
-
-
0034662510
-
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
-
Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
-
(2000)
Blood
, vol.96
, pp. 1259-1266
-
-
Kaminski, M.S.1
Estes, J.2
Zasadny, K.R.3
-
9
-
-
9744233595
-
The radioisotope contributes signif cantly to the activity of radioimmunotherapy
-
Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes signif cantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10: 7792-7798.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7792-7798
-
-
Davis, T.A.1
Kaminski, M.S.2
Leonard, J.P.3
-
10
-
-
33745102812
-
Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
-
Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006;94:1770-1776.
-
(2006)
Br J Cancer
, vol.94
, pp. 1770-1776
-
-
Buchegger, F.1
Antonescu, C.2
Delaloye, A.B.3
-
11
-
-
79958102423
-
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission
-
Buchegger F, Antonescu C, Helg C, et al. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med 2011; 52:896-900.
-
(2011)
J Nucl Med
, vol.52
, pp. 896-900
-
-
Buchegger, F.1
Antonescu, C.2
Helg, C.3
-
12
-
-
32944476224
-
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
-
Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565-7573.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7565-7573
-
-
Fisher, R.I.1
Kaminski, M.S.2
Wahl, R.L.3
-
14
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
-
Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244-1253
-
-
Cheson, B.D.1
Horning, S.J.2
Coifer, B.3
-
15
-
-
34247561116
-
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
-
Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 1009: 1804-1810.
-
(2007)
Cancer
, vol.1009
, pp. 1804-1810
-
-
Witzig, T.E.1
Molina, A.2
Gordon, L.I.3
-
16
-
-
18844435974
-
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
-
Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185-188.
-
(2005)
Cancer Biother Radiopharm
, vol.20
, pp. 185-188
-
-
Wiseman, G.A.1
Witzig, T.E.2
-
17
-
-
0028835315
-
Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
-
Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-147.
-
(1995)
J Clin Oncol
, vol.13
, pp. 140-147
-
-
Johnson, P.W.1
Rohatiner, A.Z.2
Whelan, J.S.3
-
18
-
-
20444411092
-
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
-
Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-4582.
-
(2005)
Blood
, vol.105
, pp. 4576-4582
-
-
Bennett, J.M.1
Kaminski, M.S.2
Leonard, J.P.3
-
19
-
-
4444326818
-
Follicular lymphoma international prognostic index
-
Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
-
(2004)
Blood
, vol.104
, pp. 1258-1265
-
-
Solal-Céligny, P.1
Roy, P.2
Colombat, P.3
-
20
-
-
47349105801
-
Report of a workshop on malignant lymphoma: A review of molecular and clinical risk Profiling
-
Gleissner B, Küppers R, Siebert R, et al. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk Profiling. Br J Haematol 2008; 142: 166-178.
-
(2008)
Br J Haematol
, vol.142
, pp. 166-178
-
-
Gleissner, B.1
Küppers, R.2
Siebert, R.3
-
21
-
-
70349745593
-
Follicular lymphoma international prognostic index 2:A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
-
Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2:A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4555-4562
-
-
Federico, M.1
Bellei, M.2
Marcheselli, L.3
-
22
-
-
0037464510
-
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
-
Calle EE, Rodriguez C, Walker-Turmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
-
(2003)
N Engl J Med
, vol.348
, pp. 1625-1638
-
-
Calle, E.E.1
Rodriguez, C.2
Walker-Turmond, K.3
-
23
-
-
77749306533
-
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
-
Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59:341-347.
-
(2010)
Gut
, vol.59
, pp. 341-347
-
-
Guiu, B.1
Petit, J.M.2
Bonnetain, F.3
-
24
-
-
82955201513
-
The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to inf iximab in rheumatoid arthritis:An exploratory study
-
Klaasen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to inf iximab in rheumatoid arthritis:An exploratory study. Rheumatology (Oxford) 2011;50:1487-1493.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 1487-1493
-
-
Klaasen, R.1
Cantaert, T.2
Wijbrandts, C.A.3
-
25
-
-
22544476830
-
Obesity and dose individualization in cancer chemotherapy: The role of body surface area and body mass index
-
Portugal RD. Obesity and dose individualization in cancer chemotherapy: the role of body surface area and body mass index. Med Hypotheses 2005;65:748-751.
-
(2005)
Med Hypotheses
, vol.65
, pp. 748-751
-
-
Portugal, R.D.1
-
26
-
-
58549091067
-
Dosing chemotherapy in obese patients actual versus assigned body surface area (BSA)
-
Hunter RJ, Nano MA, Taker PH, et al. Dosing chemotherapy in obese patients actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 69-78
-
-
Hunter, R.J.1
Nano, M.A.2
Taker, P.H.3
|